Nifedipine and Nicorandil in treatment of severe pre-eclampsia

Mechanisms of nifedipine, nicorandil and coenzyme q 10 in the treatment of patients with severe preeclampsia

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201803003150307

Enrollment

140

Registered

2018-02-26

Start date

2018-02-26

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Severe pre-eclampsia

Interventions

nifedipine tablets

Nicorandil tablets

nifedipine tablets plus coenzyme q10

nicorandil tablets and coenzyme q10 softgels

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Greater than 30 weeks of gestation. 2) Uncomplicated severe preeclampsia on the basis of : a- severe hypertension [systolic blood pressure (SBP) ¿160 mmHg and/or diastolic blood pressure (DBP) ¿110 mmHg]. b- clinically significant proteinuria (0.3 g or more of protein in 24-h urine collection).

Exclusion criteria

Exclusion criteria: 1) Imminence of eclampsia. 2) Chronic hypertension or other concomitant chronic diseases

Design outcomes

Primary

Measure	Time frame
control of blood pressure;changes in doppler ultrasound evaluation of the umbilical artery	—

Secondary

Measure	Time frame
changes in Serum endothelial nitric oxide synthase, antioxidant enzyme, superoxide dismutase blood level. ¿ The biomarker of oxidative stress, malondialdehyde (MDA) serum level. ¿ Platelet aggregation	—

Countries

Egypt

Contacts

Public ContactTamer M Dayem

Department of Obstetrics and gynecology, university of alexandria

tmdaeim@gmail.com00201226720766

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026